J&J spotlights infectious diseases as pipeline priority

Johnson & Johnson is putting infectious diseases in the spotlight as it outlines ambitious plans to advance new therapies for the flu, HIV and hepatitis C. During its third-quarter review of the numbers for analysts, top execs at J&J left little doubt that recent moves on the contagious disease front will be followed up with plenty of new deals.

To make its case, J&J pointed to the recent buyout pact for Crucell, the maker of vaccines and a one-time partner in a program to develop a new universal flu jab. "We want to make Crucell the center for vaccines in our pharmaceuticals business," Chief Financial Officer Dominic Caruso told analysts yesterday. J&J already sells HIV therapies, and its licensing pact with Vertex on telaprevir gives the pharma company dibs on one of the hottest hepatitis C drugs in late-stage development.

J&J told analysts that the company has 13 drugs either up for an approval or getting close to a regulatory filing. Three of those drugs are up for an approval, two more should be filed in a matter of weeks and there are eight that are expected to land at regulatory agencies between 2011 and 2013. In addition to infectious diseases, J&J has been focused on cancer, neurological disorders and immunological conditions like rheumatoid arthritis.

- here's the story from the Wall Street Journal
- get the report from the Star-Telegram

Suggested Articles

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.